PDCD1 and autoimmune disease: Still, the results of Becker-Gotot, Meissner, et al. remind us that tolerance is an active process and that understanding and application of PD-1– and PD-1L–specific reagents may be useful to induce tolerance clinically, not only in the presence of hemophilia inhibitors but also in autoimmune diseases or other adverse immune responses.